Therapy Areas: Devices
Oramed Pharmaceuticals adds new Scientific Advisory Board member
2 June 2022 -

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company, announced on Wednesday that it has added Anne Peters, MD to its Scientific Advisory Board.

Dr Peters is a professor of Medicine at the Keck School of Medicine of USC and director of the USC Clinical Diabetes Programs. She earlier directed the clinical diabetes programs at Cedars-Sinai and UCLA. She is the chair of the Endocrine Society Committee on Diabetes Devices and is on the EASD/ADA Technology Safety Committee. She is also a member of the JDRF Panel on Management of Exercise in type 1 Diabetes and a member of the ABIM Endocrinology Subspecialty Board. She has consulted for many entities, including the FDA, Optum Rx and CVS/Caremark to help guide the development and use of treatments for diabetes.

Dr Peters, said, 'I am honoured to be joining the Scientific Advisory Board of Oramed Pharmaceuticals. Their pioneering work in developing oral insulin, currently in advanced Phase 3 trials, has immense potential for improving diabetes treatments globally.'